BeOne Medicines’ Tevimbra Combination Extends Median Survival to 27 Months in Gastroesophageal Cancer Trial

Bitget2026/10/23 14:15

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold. Trade now!

A welcome pack worth 6200 USDT for new users! Sign up now!

BeOne Medicines reported sustained survival benefits for Tevimbra with Ziihera and chemotherapy in first-line HER2-positive advanced gastroesophageal adenocarcinoma.
Patients lived longer than with trastuzumab-based chemotherapy; the benefit over Ziihera with chemotherapy alone did not reach statistical significance.
No new safety signals emerged in the Phase 3 HERIZON-GEA-01 trial.
The results will be presented today at the European Society for Medical Oncology Congress 2026 in Madrid.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. BeOne Medicines AG published the original content used to generate this news brief via Business Wire (Ref. ID: 20261023068473) on October 23, 2026, and is solely responsible for the information contained therein.

Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.

Understand the market, then trade.

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold.

Trade now！

BeOne Medicines’ Tevimbra Combination Extends Median Survival to 27 Months in Gastroesophageal Cancer Trial

You may also like

Crypto prices